Limiting the development of anti-cancer drug resistance in a spatial model of micro-metastases

Abstract

Using a hybrid spatial model, we explore how chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider weakly and strongly resistant populations that can acquire drug resistance, or can harbor pre-existing resistance. Simulations uncovered several intermittent protocols that eradicate strongly acquired micrometastases resistant to continuous therapy, and also eradicate weakly resistant micrometastases (acquired and pre-existing) more efficiently than continuous therapy. These protocols may represent more effective chemotherapy schedules to limit metastatic progression.